DOCSLIB.ORG

List of Section 13F Securities, 3Rd Quarter 1997

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Section 13F Securities, 3Rd Quarter 1997 USER INFORMATION SHEET General This list of "Section 13(f) securities" as defined by Rule 13f -1(c) 117 CFR 240.13f -1(c) 1 is made available to the public pursuant to Section 13 (£1 (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)I . It is made available for use in the preparation of reports filed with the Securities and Exchange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-11 under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of September 15, 1997, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending September 30, 1997. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f) (1) and Rule 13f-1 thereunder. (1) Additions and Deletions: Revisions made to the list of Section 13(f) securities are indicated in a column titled "STATUS." The word l1ADDEDttin the status column opposite the name of a security indicates that the security has become a Section 13(f) security. The word I1DELETEDu in the status column opposite the name of a security indicates that the security ceases to be a 13(f) security since the date of the last list. (2) -of An asterisk is placed next to the name of any security having a listed option and each option is individually listed with its own CUSIP number immediately below the name of the security having the option. A manager reporting holdings of options on its Form 13F should use the CUSIP number of each option as to which holdings are reported. CUSIP descriptions and numerical identification data (copyright 1969 through 1996, American Bankers Association) are used with permission. All rights reserved. RUN DATE:10/15/97 ** LIST OF SECTION 13F SECURITIES ** PAGE 1 RUN TIME:15:39 IVMOOl CUSIP NO. ISSUER NAME ISSUER DESCRIPTION STATUS B5628B 10 4 * LERNOUT & HAUSPIE SPEECH PRODS COM B5628B 90 4 LERNOUT & HAUSPIE SPEECH PRODS CALL B5628B 95 4 LERNOUT & HAUSPIE SPEECH PRODS PUT G0070K 10 3 * ACE LTD ORD G0070K 90 3 ACE LTD CALL G0070K 95 3 ACE LTD PUT GO2702 10 1 AMERICAN CRAFT BREWING INTL COM GO2702 11 9 AMERICAN CRAFT BREWING INTL WT EXP 091101 G0352M 10 8 * AMWAY ASIA PACIFIC LTD COM G0352M 90 8 AMWAY ASIA PACIFIC LTD CALL G0352M 95 8 AMWAY ASIA PACIFIC LTD PUT GO4450 10 5 ARAMEX INTL LTD ORD GO5345 10 6 ASIA PACIFIC RES INTL HLDG LTD CL A G0535E 10 6 ASIA PACIFIC WIRE & CABLE CORP ORD G1368B 10 2 BRILLIANCE CHINA AUTO HLDG LTD COM G1863T 10 3 CAPITAL MEDIA GROUP LTD COM G1981E 10 3 CAYMAN WATER CO LTD ORD 620045 10 3 CENTRAL EUROPEAN MEDIA ENTRPRS CL A G2107X 10 8 CHINA TIRE HLDGS LTD COM 621082 10 5 CHINA YUCHAI INTL LTD COM G2109A 10 6 CHINA ENERGY RES CORP ORD 622984 10 1 * COMCAST UK CABLE PARTNERS LTD CL A 622984 90 1 COMCAST UK CABLE PARTNERS LTD CALL 622984 95 1 COMCAST UK CABLE PARTNERS LTD PUT 623257 10 1 COMMODORE HLDGS LTD ORD 623257 11 9 COMMODORE HLDGS LTD WT EXP 071501 G2519Y 10 8 CREDICORP LTD COM G2829S 10 6 DRANSFIELD CHINA PAPER CORP ORD 628471 10 3 DSG INTL LTD ORD 629526 10 3 EK CHOR CHINA MOTORCYCLE CO COM 632030 10 1 EURO TECH HOLDINGS CO LTD ORD 632030 11 9 EURO TECH HOLDINGS CO LTD WT EX 000003 G3242A 10 2 * EXEL LTD ORD G3242A 90 2 EXEL LTD CALL G3242A 95 2 EXEL LTD PUT G3287M 10 2 EZCONY INTERAMERICA INC ORD 634874 10 0 FIRST SOUTH AFRICA CORP LTD ORD 634874 11 8 FIRST SOUTH AFRICA CORP LTD WT A EX 012301 634874 12 6 FIRST SOUTH AFRICA CORP LTD WT B EX 012301 634874 13 4 FIRST SOUTH AFRICA CORP LTD UNIT EX 012301 G3774N 10 0 GCR HLDGS LTD ORD DELETED G3788V 10 6 * GEMSTAR INTL GROUP LTD 0 RD G3788V 90 6 GEMSTAR INTL GROUP LTD CALL G3788V 95 6 GEMSTAR INTL GROUP LTD PUT G3930H 10 4 * GLOBALSTAR TELECOMMUNICTNS LTD COM G3930H 90 4 GLOBALSTAR TELECOMMUNICTNS LTD CALL G3930H 95 4 GLOBALSTAR TELECOMMUNICTNS LTD PUT G4388N 10 6 * HELEN OF TROY CORP LTD COM G4388N 90 6 HELEN OF TROY CORP LTD CALL RUN DATE:10/15/97 ** LIST OF SECTION 13F SECURITIES ** PAGE 2 RUN TIME:15:39 IVMOOl CUSIP NO. ISSUER NAME ISSUER DESCRIPTION STATUS 64388N 95 6 HELEN OF TROY CORP LTD PUT 64481U 10 6 HIGHWAY HLDGS LTD ORD 64481U 11 4 HIGHWAY HLDGS LTD WT EXP 000001 647962 10 8 * INTELECT COMMUNICATIONS SYS COM 647962 90 8 INTELECT COMMUNICATIONS SYS CALL 647962 95 8 INTELECT COMMUNICATIONS SYS PUT G4802P 10 9 INTERACTIVE ENTERTAINMENT LTD COM ADDED 64933P 10 1 IPC HLDGS LTD ORD 649398 10 3 * IRIDIUM WORLD COMMUNICATIDNS CL A 649398 90 3 IRIDIUM WORLD COMMUNICATIONS CALL 649398 95 3 IRIDIUM WORLD COMMUNICATIONS PUT 649864 10 4 IWI HLDG LTD ORD 652996 10 6 KNIGHTSBRIDGE TANKERS LTD ORD G5383Q 10 1 LASALLE RE HLDGS LTD 0 RD 656462 10 7 * LORAL SPACE & COMMUNICATIONS COM 656462 90 7 LORAL SPACE & COMMUNICATIONS CALL 656462 95 7 LORAL SPACE & COMMUNICATIONS PUT 661061 10 0 * MID OCEAN LIMITED ORD SHS 661061 90 0 MID OCEAN LIMITED CALL 661061 95 0 MID OCEAN LIMITED PUT 665782 10 7 NORDIC AMERN TANKER SHIPPING WT EXP 093097 665834 12 3 NORD PAC LTD ORD NEW 66674P 10 9 NOVEL DENIM HLDGS LTD ORD ADDED 66852T 10 5 PARTNERRE LTD CUM 669586 10 8 PEAK INTL LTD ORD ADDED 67342H 10 7 RADICA GAMES LTD ORD 674966 10 3 RENAISSANCE RE HLDGS LTD COM G7805C 10 8 * SANTA FE INTL CORP ORD G7805C 90 8 SANTA FE INTL CORP CALL G7805C 95 8 SANTA FE INTL CORP PUT 681654 10 8 SINOAMERICAN TELECOM INC ORD 681772 10 8 SKY GAMES INTL LTD con DELETED G8345M 10 1 SPHERE DRAKE HLDGS LTD COM 687615 10 3 TERRA NOVA BERMUDA HLDGS LTD ORD CL A G8846W 10 3 3D LABS INC LTD ORD 689152 10 2 * HILFIGER TOMMY CORP ORD 689152 90 2 HILFIGER TOMMY CORP CALL 689152 95 2 HILFIGER TOMMY CORP PUT 689935 10 3 TRAMFORD INTL LTD ORD 689935 11 1 TRAMFORD INTL LTD WT EXP 121399 690751 10 1 * TRITON ENERGY LTD 0 RD 690751 90 1 TRITON ENERGY LTD CALL 690751 95 1 TRITON ENERGY LTD PUT 693263 10 4 VDC CORP LTD ORD ~7514~10 7 r OLICOM A/S ORD K7514Y 90 7 OLICOM A/S CALL K7514Y 95 7 OLICOM A/S PUT K7514Y 12 3 OLICOM A/S WT EXP 091200 ADDED L20708 10 0 CRONOS GROUP N V ORD RUN DATE:10/15/97 ** LIST OF SECTION 13F SECURITIES ** PAGE 3 RUN TIME:15:39 IVMOOl CUSIP NO. ISSUER NAME ISSUER DESCRIPTION STATUS L6388F 10 2 * MILLICOM INTL CELLULAR S A ORD L6388F 90 2 MILLICOM INTL CELLULAR S A CALL L6388F 95 2 MILLICOM INTL CELLULAR S A PUT L8137H 10 8 SCANDINAVIAN BROADCASTING SYS ORD L8873E 10 3 STOLT COMEX SEAWAY SA COM L88742 10 8 STOLT NIELSEN S A COM M01575 10 5 ACCENT SOFTWARE INTL LTD COM M01575 15 4 ACCENT SOFTWARE INTL LTD UNIT EX 071998 M0392N 10 1 ALADDIN KNOWLEDGE SYS LTD ORD M14925 10 7 AREL COMMUNICATIONS & SOFTWARE COM M14925 11 5 AREL COMMUNICATIONS & SOFTWARE WT A EX 120197 M14950 10 5 ARIELY ADVERTISING LTD ORD M15015 10 6 ARZAN INTL (1991) LTD ORD M15015 11 4 ARZAN INTL (1991) LTD WT EXP 031299 M20115 10 7 BOS BETTER ONLINE SOLUTIONS ORD M20115 11 5 BOS BETTER ONLINE SOLUTIONS WT EXP 040299 M20514 10 1 BVR TECHNOLOGIES LTD ORD M22465 10 4 * CHECK POINT SOFTWARE TECH LTD ORD M22465 90 4 CHECK POINT SOFTWARE TECH LTD CALL M22465 95 4 CHECK POINT SOFTWARE TECH LTD PUT M23798 10 7 CIMATRON LTD ORD M26763 10 8 CRYSTAL SYS SOLUTIONS LTD DRD M3040Q 10 4 EDUSOFT LTD ORD M3752J 10 8 ELBIT LTD ORD M37576 10 1 ELBIT VISION SYS LTD ORD M3760D 10 1 ELBIT SYS LTD ORD M37605 10 8 ELBIT MEDICAL IMAGING LTD ORD M3909Q 10 4 ELECTROCHEMICAL INDS 1952 LTD ORD M40105 11 2 ELRON ELECTRONIC INDS WT EXP 090198 M40168 10 2 ELSCINT LTD NEW ORD M40184 10 9 ELTEK LTD ORD M40868 10 7 * ESC MEDICAL SYS LTD ORD M40868 90 7 ESC MEDICAL SYS LTD CALL M40868 95 7 ESC MEDICAL SYS LTD PUT M4095C 10 7 ESHED ROBOTEC 1982 LTD ORD M4113L 10 5 ETZ LAVUD LTD CL A M4113L 11 3 ETZ LAVUD LTD COM M47298 10 0 GALILEO TECHNOLDGY LTD ORD ADDED M49319 10 2 GENESIS DEV & CONSTRUCTION LTD ORD M49319 11 0 GENESIS DEV & CONSTRUCTION LTD WT A EX 000002 M49319 12 8 GENESIS DEV & CONSTRUCTION LTD WT B EX 000002 M49319 13 6 GENESIS DEV & CONSTRUCTION LTD UNIT EX 000002 M51474 10 0 * GILAT SATELLITE NETWORKS LTD ORD M51474 90 0 GILAT SATELLITE NETWORKS LTD CALL M51474 95 0 GILAT SATELLITE NETWORKS LTD PUT M52523 10 3 WILL1 G FOOD INTL LTD ORD M52523 11 1 WILL1 G FOOD INTL LTD WT EX 000002 M53070 10 4 HOME CTRS DIY LTD ORD M53301 13 7 IDAN SOFTWARE INDS-IS1 LTD ORD NEW RUN DATE:10/15/97 ** LIST OF SECTION 13F SECURITIES ** PAGE 4 RUN TIME:15:39 IVMOOl CUSIP NO. ISSUER NAME ISSUER DESCRIPTIDN STATUS M5733B 10 4 ISG INTL SOFTWARE GROUP LTD ORD M6706C 10 3 LANOPTICS LTD ORD M6777Q 10 6 LOGAL EDUCATIONAL SOFTWARE SYS ORD M6786D 10 4 MAGAL SECURITY SYS LTD ORD M6879H 10 3 MEDIS EL LTD ORD M69065 10 6 MEMCO SOFTWARE LTD ORD M69676 10 0 HER TELEMANAGEMENT SOLUTIONS ORD M7061C 10 0 M SYS FLASH DISK PIONEERS LTD ORD M74295 10 2 NEW DIMENSION SOFTWARE LTD ORD M7515Y 10 4 NUR ADVANCED TECHNOLOGIES LTD ORD M75252 10 2 OPTISYSTEMS SOLUTIONS LTD ORD M75252 11 0 OPTISYSTEMS SOLUTIONS LTD WT EXP 000002 M75253 10 0 * ORBOTECH LTD ORD M75253 90 0 ORBOTECH LTD CALL M75253 95 0 ORBOTECH LTD PUT M7531S 10 7 ORCKIT COMMUNICATIONS LTD COM M75495 10 7 ORGENICS LTD ORD M78675 10 1 PER10 PRODS LTD ORD M8215N 10 9 RIT TECHNOLOGIES LTD ORD ADDED M82400 10 8 SCANVEC CO 1990 LTD ORD M84116 10 8 SILICOM LTD ORD M84116 11 6 SILICOM LTD WT EXP 000098 M87340 10 1 TADIRAN TELECOMMUNICATIONS LTD ORD M8737E 10 8 TARO PHARMACEUTICAL INDS LTD ORD M8740S 14 4 TAT TECHNOLOGIES LTD ORD SHS M8743P 10 5 TECNOMATIX TECHNOLOGIES LTD ORD M8762U 10 0 Z TELEDATA COMMUNICATION LTD ORD M8762U 90 0 TELEDATA COMMUNICATION LTD CALL M8762U 95 0 TELEDATA COMMUNICATION LTD PUT M87896 10 2 TOP IMAGE SYSTEMS LTD ORD M87896 11 0 TOP IMAGE SYSTEMS LTD WT EXP 000099 M87915 10 0 * TOWER SEMICONDUCTOR LTD
Load more

Recommended publications
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Listing of Global Companies with Ongoing Government Activity
    COMPANY LINE OF BUSINESS TICKER A & A BIOTECHNOLOGY S C ADAM BURKIEWICZ MIKOLAJ BURKIEWICZ PHARMACEUTICAL PREPARATIONS A & A GLOBAL INDUSTRIES, INC. AUTOMATIC VENDING MACHINES, NSK A & J ENTERPRISES PHARMACEUTICAL PREPARATIONS A & S INTERNATIONAL 2000 S.R.L. PHARMACEUTICAL PREPARATIONS A & S PHARMACEUTICAL CORP. PHARMACEUTICAL PREPARATIONS A & T MARKETING INC. COMPUTER INTEGRATED SYSTEMS DESIGN, NSK A & T SYSTEMS, INC. TELEPHONE COMMUNICATION, EXCEPT RADIO A & Z PHARMACEUTICAL INC. PHARMACEUTICAL PREPARATIONS A A INTERNATIONAL PHARMACEUTICAL PREPARATIONS A AND V, INC. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC A AROGYA HARBALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS A B ENTERPRISES PHARMACEUTICAL PREPARATIONS A B I HERBAL PRODUCTS MEDICINALS AND BOTANICALS, NSK A B S REMEDIES PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK A BEAT FOR YOUR FEET, INC. COIN-OPERATED LAUNDRIES AND CLEANING, NSK A BUCKHEAD BUS COMPANY LOCAL PASSENGER TRANSPORTATION, NEC A C C VIEIRA PROTESE ME MEDICINALS AND BOTANICALS, NSK A C CONSULTING PHARMACEUTICAL PREPARATIONS A C E DIAGNOSTICS & BIOTECH LIMITED PHARMACEUTICAL PREPARATIONS A C E PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS A C PHARMACEUTICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS A CUT ABOVE LANDSCAPE LAWN AND GARDEN SERVICES A D C O MARKETING INC NONDURABLE GOODS, NEC, NSK A G HERBALS PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK A G PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS A H C PHARMACAL, INC PHARMACEUTICAL PREPARATIONS A H SYSTEMS INC INSTRUMENTS TO MEASURE ELECTRICITY A HOUSE OF AYURVEDIC
    [Show full text]
  • SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PLC (Exact name of registrant as specified in its charter) Jersey (Channel Islands) 98-0601486 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 5 Riverwalk, Citywest Business Campus, Dublin +353 1 429 7700 24, Republic of Ireland (Address of principal executive offices and zip code) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing three NASDAQ Global Select Market Ordinary Shares 5 pence par value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) 1 Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [X] No [ ] Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X] Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Bioworld Insight
    BioWorld Insight The news source of record covering the development of innovative human therapies October 30, 2017 Actionable Intelligence • Incisive Analysis Volume 25, No. 44 Society needs to urgently address antimicrobial resistance By Peter Winter, Editor The challenge of antimicrobial resistance (AMR) is one we need to urgently solve. In the U.S., the CDC estimates at least 2 million people become infected with bacteria that are resistant to currently available antibiotic therapies annually and approximately 23,000 people will die each year as a direct result of those infections. The threat of AMR has certainly been recognized worldwide and has become a top priority for global policy and public health. See AMR, page 3 Cheaper and faster also testing the drug in combination with immune Oncology drugs checkpoint inhibitors. “You often hear people say inhibiting PD-1 move to China seeking and CCR4 is like reducing the brake on a car. Plinabulin is like adding the fuel,” Huang patients and approvals explained. Nevertheless, she sees opportunities By Brian Orelli, Staff Writer for plinabulin in combination with both With a third of the world’s cancer patients residing chemotherapy and immune checkpoint inhibitors, Inside in China and upward of half of them enrolling in “Chemotherapy isn’t going away; nivolumab only clinical trials, small U.S.-based companies are has a 20 percent response rate.” Money raised by biotech looking across the Pacific to test their oncology On the neutropenia side, last week the company in 2017 drug candidates. enrolled its first patient in China in the global page 4 The advantages of lower cost and increased speed phase II/III trial testing plinabulin as a prevention of chemotherapy-induced neutropenia.
    [Show full text]
  • Lishing Group Group Nature Publishing
    PEOPLE Paul L. Berns (left) has been appointed Allos Therapeutics’ NitroMed (Lexington, MA, USA) has (Westminster, CO, USA) president, CEO and member of the board announced that Argeris (Jerry) Karabelas, of directors. He brings close to 15 years of pharmaceutical industry currently chairman of the board of directors, experience to Allos, holding senior management positions at Abbott has been appointed interim CEO, succeed- Laboratories, BASF Pharmaceuticals and Bristol-Myers Squibb. Mr. ing Michael Loberg, who resigned from his Berns was most recently president, CEO and a member of the board position as president, CEO and director of of directors of Bone Care International. With Mr. Berns’ appointment, NitroMed. In addition, Kenneth Bate, formerly Michael E. Hart has resigned his positions as president, CEO and CFO of Millennium Pharmaceuticals, has been CFO, and David C. Clark, the company’s controller and treasurer, has named chief operating officer and CFO, follow- been appointed to serve as interim CFO until a permanent replacement is found. ing the departure of Lawrence Bloch as CFO and chief business officer. Morphotek (Exton, PA, USA) has announced Privately held NascaCell IP (Munich) has was most recently head of clinical operations the appointment of Robert Radie as chief announced the appointment of cofounder at Vical. business officer and the promotion of Luigi http://www.nature.com/naturebiotechnology Michael Blind to the position of CEO. Dr. Grasso to senior vice president of R&D. Mr. Blind was previously responsible for research VLST Corp. (Seattle, WA, USA) has announced Radie was most recently senior vice president and development activities at NascaCell.
    [Show full text]
  • Cancer Vaccine Therapies: Failures and Future Opportunities Michael D
    Cancer Vaccine Therapies: Failures and Future Opportunities Michael D. Becker, Janet Dally, and Jeffrey Martini, Ph.D. Michael D. Becker President & CEO [email protected] Janet Dally Senior Vice President [email protected] Jeffrey Martini, Ph.D. Vice President [email protected] MD Becker Partners LLC 12 Penns Trail, #231 Newtown, PA 18940 Main phone: 267-756-7094 Email: [email protected] Web: www.mdbpartners.com www.mdbpartners.com Copyright © 2010 MD Becker Partners LLC All rights reserved MD Becker Partners LLC [This page intentionally left blank] Cancer Vaccine Therapies: Failures and Future Opportunities Page 2 MD Becker Partners LLC MD Becker Partners’ reports are limited publications that contain valuable information provided to a select group of customers. Our reports are for our customers’ internal use and not for general publication or disclosure to third parties. No part of this report may be given, lent, resold, or disclosed to non-customers without written permission. Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the permission of the publisher. For additional information, please refer to Appendix G: Legal Disclaimer. For information regarding permission, write: MD Becker Partners LLC 12 Penns Trail, #231 Newtown, PA 18940 Main phone: 267-756-7094 Email: [email protected] Web: www.mdbpartners.com MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry, including pharmaceuticals, biotechnology, and medical devices. We also work with venture capitalists, institutional investors, and others that provide capital to these companies.
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • Company Name Ticker Symbol Industry Name Adstar Inc ADST
    Company Name Ticker Symbol Industry Name SIC Code AdStar Inc ADST Advertising 7310 ActionView Int'l Inc AVEW Advertising 7310 Betawave Corporation BWAV Advertising 7310 V Media Corporation CMDI Advertising 7310 ChinaNet Online Holdings Inc CNET Advertising 7310 Dynamic Response Group Inc DRGZ Advertising 7310 Interep National Radio Sales I IREP Advertising 7310 MaxWorldwide Inc MAXW Advertising 7310 Vertical Branding Inc. VBDG Advertising 7310 Digital Generation Inc DGIT Advertising 7310 Clicker Inc CLKZ Advertising 7310 Int'l Commercial Television ICTL Advertising 7310 MSGI Security Solutions Inc MSGI Advertising 7310 mktg inc. CMKG Advertising 7310 Coupon Express Inc CPXP Advertising 7310 Klever Marketing Inc KLMK Advertising 7310 Tiger Media Inc. IDI Advertising 7310 VisionChina Media Inc VISN Advertising 7310 Onstream Media Corporation ONSM Advertising 7310 Monster Worldwide MWW Advertising 7310 Wilhelmina International Corp WHLM Advertising 7310 Marchex Inc. MCHX Advertising 7310 Clear Channel Outdoor Holding CCO Advertising 7310 Lamar Advertising LAMR Advertising 7310 Global Sources GSOL Advertising 7310 Interpublic Group IPG Advertising 7310 Valassis Communic. VCI Advertising 7310 Harte-Hanks HHS Advertising 7310 ValueClick Inc. VCLK Advertising 7310 National CineMedia NCMI Advertising 7310 WPP PLC ADR WPPGY Advertising 7310 Omnicom Group OMC Advertising 7310 American Ammunition Inc. AAMUQ Aerospace/Defense 3720 Air Lease Corp AL Aerospace/Defense 3720 Applied Science Products Inc APLD Aerospace/Defense 3720 Bulova Technologies Group Inc BLVT Aerospace/Defense 3720 Erickson Air-Crane Inc. EAC Aerospace/Defense 3720 E'Prime Aerospace Corporation EPEO Aerospace/Defense 3720 Environmental Tectonics Corp. ETCC Aerospace/Defense 3720 Huntington Ingalls HII Aerospace/Defense 3720 Oakridge Holdings Inc OKRG Aerospace/Defense 3720 OPT Sciences Corp OPST Aerospace/Defense 3720 Passur Aerospace Inc PSSR Aerospace/Defense 3720 American Defense Systems Inc.
    [Show full text]
  • BIOTECHNOLOGY Presented by America’S Biopharmaceutical Research Companies
    2011 REPORT 2011 Medicines in Development BIOTECHNOLOGY presented by america’s biopharmaceutical research companies Biotechnology Research Promises to Bolster the Future of Medicine with More Than 900 Medicines and Vaccines in Development In the human body there are Biotechnology Medicines 12 trillion cells, in Development 200,000 proteins and 25,000 genes 300 298 America’s biopharmaceutical research compa- The biotechnology medicines now in develop- nies are using biotechnology to develop 901 ment make use of these and other state-of- medicines and vaccines targeting more than the-art approaches. For example: 100 diseases. Biotechnology medicines are developed through biological processes using $JHQHWLFDOO\PRGL¿HGYLUXVEDVHG living cells or organisms, rather than the tra- vaccine to treat melanoma. ditional chemical synthesis approach. These $PRQRFORQDODQWLERG\IRUWKHWUHDWPHQW medicines in development are either in human of cancer and asthma. clinical trials or under review by the U.S. Food and Drug Administration. $QDQWLVHQVHPHGLFLQHIRUWKHWUHDWPHQW of cancer. Biotechnology medicines use many different $UHFRPELQDQWIXVLRQSURWHLQWRWUHDW 78 cutting-edge approaches to treat disease. A age-related macular degeneration. 64 monoclonal antibody is a laboratory-made 50 version of the naturally occurring immune These are only a few examples of the new system protein that binds to and neutralizes ways America’s biopharmaceutical research foreign invaders. Interferons are proteins that companies are attacking disease through bio- 23 interfere with the ability of a cell to reproduce. technology. The 901 biotechnology medicines Antisense drugs are medicines that interfere and vaccines in development promise to push with the communication process that tells a the frontiers of science and potentially bring e y cell to produce an unwanted protein.
    [Show full text]
  • [ Emc-Lusinnufll'lergcrta'rgets
    US 20070255633Al (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2007/0255633 A1 Kridel (43) Pub. Date: NOV. 1, 2007 (54) SYSTEMS AND METHODS FOR INVESTING (52) US. Cl. ....................................................... .. 705/35 (76) Inventor: FIVJigiam J. Kridel, New York, NY (57) ABSTRACT The present invention discloses systems and methods for Correspondence Address? creating and managing ?nancial instruments and indexes PAUL’ HASTINGS’ JANOFSKY & WALKER comprised of securities for companies in subsectors of the LLP economy. These ?nancial instruments alloW investment in R0' BOX 919092 subsectors of the economy Will still being able to minimize SAN DIEGO CA 92191-9092 ’ risk by diversi?cation. The indexes serve as benchmarks for (21) App1_ NO; 11/465,768 companies in the subsectors of the economy. A procedure may be used to identify the securities to include in the (22) Filed: Allg- 18, 2006 ?nancial instruments. This procedure may include (a) iden _ _ tifying securities for companies in a sector of the economy; Related U's‘ Apphcatlon Data (b) limiting the identi?ed securities to those for companies (60) Provisional application No. 60/778,492, ?led on Mar. in a SubSeCIOr Of the SBCIOI‘ Of the economy; (0) applying 1, 2006. focus rules to further limit the identi?ed securities to those _ _ _ _ for companies Who are focused in the subsector of the Pubhcatlon Classl?catlon economy; and (d) limiting the securities included in the (51) Int, Cl, ?nancial instrument or index to those that satisfy other G06Q 40/00 (2006.01) objective criteria. ETF RULE. SET->| APPLICATION’ ' "1 _.
    [Show full text]
  • 2020 December
    Asset Detail Acct Base Currency Code : USD ALL KR2 AND KR3 - KR2GALLKRS00 As Of Date : 12/31/2020 Accounting Status : PRELIMINARY Mellon Security Base Market . Shares/Par Security ID Description Value ALTERNATIVE INVESTMENTS ARROWMARK FUND I 552,069,089.000 552,069,089.00 BLACKSTONE STRAT OPP 2,525,216.120 2,525,216.12 GOVERNORS LANE FUNDÉÉÉÉÉÉÉÉ 358,526.780 358,526.78 LUXOR CAPITAL PARTNERS OFFSHORE LTDD 1,459,032.030 1,459,032.03 MAGNETAR MTP EOF II 35,678,607.620 35,678,607.62 MYRIAD OPPORTUNITIES 48,648,563.010 48,648,563.01 NORTHERN TRUST LITIGATION CREDIT 2.000 0.00 PINE RIVER FUND LTD 139,672.780 139,672.78 SRS PARTNERS USÉÉÉÉ 5,994,083.350 5,994,083.35 TOTAL ALTERNATIVE INVESTMENTS 646,872,792.690 646,872,790.69 CASH & CASH EQUIVALENTS ABN AMRO FDG USA DISC 01/04/2021 3,600,000.000 3,598,695.00 ABN AMRO FDG USA DISC 02/08/2021 2,600,000.000 2,598,700.00 ATLANTIC ASSET DISC 02/10/2021 3,800,000.000 3,797,973.34 AUSTRALIA & NZ BK DISC 03/17/2021 2,700,000.000 2,698,582.50 BANK OF MONTREAL DISC 01/05/2021 3,850,000.000 3,848,272.85 BARCLAYS BANK DISC 01/11/2021 3,750,000.000 3,748,031.25 BARCLAYS BANK DISC 03/16/2021 2,800,000.000 2,798,180.00 BLACKROCK MONEY MARKET FD B 94.450 94.45 BPCE DISC 03/03/2021 3,900,000.000 3,897,102.08 CANTOR REPO A TRI REPO 0.100% 01/04/2021 DD 12/30/20 290,200,000.000 290,200,000.00 CNH/USD SPOT OPTION 2021 PUT APR 21 006.650 ED 041521 2,324,300.000 0.00 COLLATERALIZED CP DISC 02/17/2021 1,200,000.000 1,199,488.00 CONAGRA FOODS DISC 01/05/2021 1,537,000.000 1,536,684.06 EB TEMP IVN FD VAR RT 12/31/49
    [Show full text]
  • List of Section 13F Securities, First Quarter 2003
    OFFICIAL LIST OF SECTION 13(F) SECURITIES USER INFORMATION SHEET General This list of "Section 13(f) securities" as defined by Rule 13f-I (c) [17 CFR 240.13f-l(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [I5 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.1 3f-11 under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of Marchl5, 2003, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 30, 2003. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(l) and Rule 13f-I] thereunder. Features (1) Additions and Deletions: Revisions made to the list of Section 13(f) securities are indicated in a column titled "STATUS." The word "ADDED" in the status column opposite the name of a security indicates that the security has become a Section 13(f) security. The word "DELETED" in the status column opposite the name of a security indicates that the security ceases to be a 13(f) security since the date of the last list. (2) List of options: An asterisk is placed next to the name of any security having a listed option and each option is individually listed with its own CUSlP number immediately below the name of the security having the option.
    [Show full text]